Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Dr. Hönle

DB:HNL
Snowflake Description

Excellent balance sheet and good value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HNL
DB
€146M
Market Cap
  1. Home
  2. DE
  3. Capital Goods
Company description

Dr. Hönle AG operates in the UV market worldwide. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
  • Dr. Hönle has significant price volatility in the past 3 months.
HNL Share Price and Events
7 Day Returns
6%
DB:HNL
9.2%
DE Electrical
9.9%
DE Market
1 Year Returns
-42.2%
DB:HNL
-8.2%
DE Electrical
-17.5%
DE Market
HNL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Dr. Hönle (HNL) 6% -27.3% -36.7% -42.2% -16.6% 27.6%
DE Electrical 9.2% -20.6% -35.2% -8.2% -43.7% -44.1%
DE Market 9.9% -16.6% -24.8% -17.5% -24.5% -28.1%
1 Year Return vs Industry and Market
  • HNL underperformed the Electrical industry which returned -8.2% over the past year.
  • HNL underperformed the Market in Germany which returned -17.5% over the past year.
Price Volatility
HNL
Industry
5yr Volatility vs Market
Related Companies

HNL Value

 Is Dr. Hönle undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Dr. Hönle to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Dr. Hönle.

DB:HNL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:HNL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Electrical Unlevered Beta Simply Wall St/ S&P Global 1.12
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.118 (1 + (1- 30%) (21.88%))
1.194
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.19
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.194 * 5.44%)
6.11%

Discounted Cash Flow Calculation for DB:HNL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Dr. Hönle is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:HNL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.11%)
2020 -1.20 Analyst x1 -1.13
2021 9.20 Analyst x1 8.17
2022 7.89 Est @ -14.25% 6.60
2023 7.09 Est @ -10.09% 5.60
2024 6.58 Est @ -7.18% 4.90
2025 6.25 Est @ -5.14% 4.38
2026 6.01 Est @ -3.72% 3.97
2027 5.85 Est @ -2.72% 3.64
2028 5.73 Est @ -2.02% 3.36
2029 5.64 Est @ -1.53% 3.12
Present value of next 10 years cash flows €42.00
DB:HNL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €5.64 × (1 + -0.39%) ÷ (6.11% – -0.39%)
€86.55
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €86.55 ÷ (1 + 6.11%)10
€47.85
DB:HNL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €42.00 + €47.85
€89.85
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €89.85 / 5.51
€16.3
DB:HNL Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:HNL represents 0.99279x of XTRA:HNL
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99279x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 16.30 x 0.99279
€16.18
Value per share (EUR) From above. €16.18
Current discount Discount to share price of €27.55
= -1 x (€27.55 - €16.18) / €16.18
-70.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Dr. Hönle is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Dr. Hönle's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Dr. Hönle's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:HNL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €1.90
XTRA:HNL Share Price ** XTRA (2020-03-31) in EUR €27.75
Germany Electrical Industry PE Ratio Median Figure of 6 Publicly-Listed Electrical Companies 22.57x
Germany Market PE Ratio Median Figure of 399 Publicly-Listed Companies 16.31x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Dr. Hönle.

DB:HNL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:HNL Share Price ÷ EPS (both in EUR)

= 27.75 ÷ 1.90

14.64x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dr. Hönle is good value based on earnings compared to the DE Electrical industry average.
  • Dr. Hönle is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Dr. Hönle's expected growth come at a high price?
Raw Data
DB:HNL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 14.64x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
33.5%per year
Germany Electrical Industry PEG Ratio Median Figure of 5 Publicly-Listed Electrical Companies 1x
Germany Market PEG Ratio Median Figure of 255 Publicly-Listed Companies 1.18x

*Line of best fit is calculated by linear regression .

DB:HNL PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 14.64x ÷ 33.5%

0.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dr. Hönle is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Dr. Hönle's assets?
Raw Data
DB:HNL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €16.95
XTRA:HNL Share Price * XTRA (2020-03-31) in EUR €27.75
Germany Electrical Industry PB Ratio Median Figure of 14 Publicly-Listed Electrical Companies 1.69x
Germany Market PB Ratio Median Figure of 571 Publicly-Listed Companies 1.43x
DB:HNL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:HNL Share Price ÷ Book Value per Share (both in EUR)

= 27.75 ÷ 16.95

1.64x

* Primary Listing of Dr. Hönle.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dr. Hönle is good value based on assets compared to the DE Electrical industry average.
X
Value checks
We assess Dr. Hönle's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Electrical industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Electrical industry average (and greater than 0)? (1 check)
  5. Dr. Hönle has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

HNL Future Performance

 How is Dr. Hönle expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
33.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Dr. Hönle expected to grow at an attractive rate?
  • Dr. Hönle's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Dr. Hönle's earnings growth is expected to exceed the Germany market average.
  • Dr. Hönle's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:HNL Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:HNL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 33.5%
DB:HNL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 10.5%
Germany Electrical Industry Earnings Growth Rate Market Cap Weighted Average 69.2%
Germany Electrical Industry Revenue Growth Rate Market Cap Weighted Average 12.4%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:HNL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:HNL Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-09-30 168 1
2023-09-30 157 1
2022-09-30 143 1
2021-09-30 128 25 19 1
2020-09-30 111 23 13 1
2020-03-31
DB:HNL Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 103 13 10
2019-09-30 108 17 12
2019-06-30 119 16 17
2019-03-31 122 18 18
2018-12-31 127 27 21
2018-09-30 127 24 22
2018-06-30 119 22 19
2018-03-31 116 18 17
2017-12-31 110 8 14
2017-09-30 102 7 10
2017-06-30 97 5 8
2017-03-31 96 8 9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Dr. Hönle's earnings are expected to grow significantly at over 20% yearly.
  • Dr. Hönle's revenue is expected to grow by 10.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:HNL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Dr. Hönle Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:HNL Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-09-30
2023-09-30
2022-09-30
2021-09-30 3.35 3.35 3.35 1.00
2020-09-30 2.32 2.32 2.32 1.00
2020-03-31
DB:HNL Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 1.90
2019-09-30 2.26
2019-06-30 3.05
2019-03-31 3.29
2018-12-31 3.84
2018-09-30 3.94
2018-06-30 3.41
2018-03-31 3.15
2017-12-31 2.57
2017-09-30 1.89
2017-06-30 1.54
2017-03-31 1.56

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Dr. Hönle will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Dr. Hönle's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Dr. Hönle has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

HNL Past Performance

  How has Dr. Hönle performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Dr. Hönle's growth in the last year to its industry (Electrical).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Dr. Hönle's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • Dr. Hönle's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Dr. Hönle's 1-year earnings growth is negative, it can't be compared to the DE Electrical industry average.
Earnings and Revenue History
Dr. Hönle's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Dr. Hönle Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:HNL Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 103.09 10.45 36.99
2019-09-30 107.85 12.48 37.53
2019-06-30 119.18 16.81 38.37
2019-03-31 122.02 18.13 38.81
2018-12-31 127.42 21.15 38.51
2018-09-30 126.71 21.74 37.56
2018-06-30 118.85 18.78 36.37
2018-03-31 115.63 17.38 35.47
2017-12-31 109.54 14.16 34.84
2017-09-30 102.18 10.43 34.38
2017-06-30 96.96 8.47 34.13
2017-03-31 96.06 8.57 33.61
2016-12-31 93.17 7.91 33.20
2016-09-30 93.64 8.28 32.84
2016-06-30 93.98 9.25 32.07
2016-03-31 93.05 9.46 31.65
2015-12-31 93.34 10.26 31.31
2015-09-30 92.53 10.13 30.84
2015-06-30 88.46 8.41 30.14
2015-03-31 85.89 7.77 29.81
2014-12-31 84.06 6.48 29.30
2014-09-30 82.46 6.26 29.24
2014-06-30 80.24 7.66 29.10
2014-03-31 81.57 7.40 28.77
2013-12-31 81.23 7.29 28.40
2013-09-30 78.13 6.62 27.36
2013-06-30 80.75 6.19 26.66

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Dr. Hönle has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Dr. Hönle used its assets more efficiently than the DE Electrical industry average last year based on Return on Assets.
  • Dr. Hönle's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Dr. Hönle's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Electrical industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Dr. Hönle has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

HNL Health

 How is Dr. Hönle's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Dr. Hönle's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Dr. Hönle is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Dr. Hönle's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Dr. Hönle's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Dr. Hönle Company Filings, last reported 3 months ago.

DB:HNL Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 93.57 26.50 14.02
2019-09-30 90.12 21.97 14.58
2019-06-30 89.46 12.27 15.42
2019-03-31 88.43 11.84 15.26
2018-12-31 91.21 6.52 15.55
2018-09-30 87.25 7.16 12.04
2018-06-30 80.00 7.57 13.88
2018-03-31 77.17 8.37 11.32
2017-12-31 75.00 8.34 5.83
2017-09-30 69.78 9.82 5.22
2017-06-30 64.57 10.97 3.84
2017-03-31 62.63 10.86 3.63
2016-12-31 63.39 9.66 6.56
2016-09-30 61.67 9.37 6.52
2016-06-30 60.36 10.13 5.61
2016-03-31 58.11 10.97 4.28
2015-12-31 59.49 10.85 8.01
2015-09-30 57.51 11.21 7.46
2015-06-30 53.64 11.11 3.87
2015-03-31 51.82 11.62 3.20
2014-12-31 51.64 13.32 4.65
2014-09-30 49.72 12.91 5.69
2014-06-30 48.59 12.68 4.17
2014-03-31 46.87 11.28 4.41
2013-12-31 48.52 8.69 4.40
2013-09-30 46.87 9.32 4.38
2013-06-30 45.41 8.06 4.38
  • Dr. Hönle's level of debt (28.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (25.8% vs 28.3% today).
  • Debt is well covered by operating cash flow (49.2%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 180.7x coverage).
X
Financial health checks
We assess Dr. Hönle's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Dr. Hönle has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

HNL Dividends

 What is Dr. Hönle's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.88%
Current annual income from Dr. Hönle dividends. Estimated to be 3.06% next year.
If you bought €2,000 of Dr. Hönle shares you are expected to receive €58 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Dr. Hönle's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.68%).
  • Dr. Hönle's dividend is below the markets top 25% of dividend payers in Germany (4.97%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:HNL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Germany Electrical Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2%
Germany Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.8%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:HNL Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-09-30
2023-09-30
2022-09-30
2021-09-30 0.90 1.00
2020-09-30 0.80 1.00
2020-03-31
DB:HNL Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2020-01-28 0.800 2.225
2019-01-28 0.800 1.600
2013-01-28 0.500 3.938
2009-10-15 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Dr. Hönle has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Dr. Hönle only paid a dividend in the past 7 years.
Current Payout to shareholders
What portion of Dr. Hönle's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.4x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Dr. Hönle's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Dr. Hönle afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Dr. Hönle has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

HNL Management

 What is the CEO of Dr. Hönle's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Dr. Hönle has no CEO, or we have no data on them.
Management Team

Norbert Haimerl

TITLE
CFO, MD
COMPENSATION
€898K
AGE
57

Heiko Runge

TITLE
CTO, MD of Sales & Technology and Member of Management Board
COMPENSATION
€866K
AGE
55
TENURE
20.2 yrs

Peter Weinert

TITLE
Head of Investor Relations
Board of Directors Tenure

Average tenure of the Dr. Hönle board of directors in years:

5
Average Tenure
  • The tenure for the Dr. Hönle board of directors is about average.
Board of Directors

Karl Honle

TITLE
Chairman of Supervisory Board
TENURE
5 yrs

Gunther Henrich

TITLE
Vice Chairman of Supervisory Board
TENURE
5 yrs

Bernhard Gimple

TITLE
Member of Supervisory Board
TENURE
5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Dr. Hönle's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Dr. Hönle has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

HNL News

Simply Wall St News

HNL Company Info

Description

Dr. Hönle AG operates in the UV market worldwide. It operates through three segments: Equipment & Systems, Glass & Lamps, and Adhesives. The Equipment & Systems segment offers UV equipment and systems, LED-UV units, IR units, inert systems, disinfection systems, solar simulation systems and light fixtures, lighting systems, UV measuring technology products, UV-adhesives, and components and replacement parts. This segment also provides hot air systems, and powder spraying and extraction systems for sheet-fed offset printing; UV dryers for Web printing; UV systems with nitrogen inertisation; and drying systems. Its products are used for drying inks and coatings, curing adhesives and plastics, disinfecting surfaces, and sunlight simulation. The Glass & Lamps segment offers UV low and medium pressure lamps; infrared emitters; electronic power supplies; UV sensors and measuring technology products; UV measuring devices; and submersible and immersion tube systems, as well as accessories. This segment also provides UV bulbs; and quartz glass tubing and rods for the lamp, automotive, semiconductor, and fiber cable industries. The Adhesives segment offers industrial, UV, medical grade, and conductive adhesives; dosing systems; potting and sealing compounds; and UV curing units. Dr. Hönle AG was founded in 1976 and is headquartered in Gräfelfing, Germany.

Details
Name: Dr. Hönle AG
HNL
Exchange: DB
Founded: 1976
€146,339,723
5,511,854
Website: http://www.hoenle.de
Address: Dr. Hönle AG
Lochhamer Schlag 1,
Gräfelfing,
Bavaria, 82166,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA HNL Bearer Shares XETRA Trading Platform DE EUR 24. Jan 2001
OTCPK DRHN.F Bearer Shares Pink Sheets LLC US USD 24. Jan 2001
DB HNL Bearer Shares Deutsche Boerse AG DE EUR 24. Jan 2001
LSE 0O27 Bearer Shares London Stock Exchange GB EUR 24. Jan 2001
BATS-CHIXE HNLd Bearer Shares BATS 'Chi-X Europe' GB EUR 24. Jan 2001
Number of employees
Current staff
Staff numbers
589
Dr. Hönle employees.
Industry
Electrical Components and Equipment
Capital Goods
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 21:31
End of day share price update: 2020/03/31 00:00
Last estimates confirmation: 2020/02/24
Last earnings filing: 2020/02/21
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.